Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123280) titled 'A prospective, exploratory study of Retlirafusp alfa combined with FLOT as neoadjuvant therapy for patients with resectable adenocarcinoma of the esophagogastric junction' on April 23.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Xijing Hospital, Air Force Medical University

Condition: Adenocarcinoma of the Esophagogastric Junction

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-04-25

Target Sample Size: Trial Group:37;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=318867

Disclaimer: Curated b...